Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Suppressing corrosion in primary aluminum-air batteries via oil displacement.

Hopkins BJ, Shao-Horn Y, Hart DP.

Science. 2018 Nov 9;362(6415):658-661. doi: 10.1126/science.aat9149.

PMID:
30409879
2.

Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.

Scott MJ, Xiang H, Hart DP, Palmer B, Collins PW, Stephensen D, Sima CS, Hay CRM.

Haemophilia. 2018 Nov 8. doi: 10.1111/hae.13616. [Epub ahead of print]

PMID:
30408835
3.

Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A.

Hart DP, Uzun N, Skelton S, Kakoschke A, Househam J, Moss DS, Shepherd AJ.

Haematologica. 2018 Sep 28. pii: haematol.2018.195669. doi: 10.3324/haematol.2018.195669. [Epub ahead of print]

4.

Common themes and challenges in hemophilia care: a multinational perspective.

Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola Ettingshausen C, Hart DP, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R.

Hematology. 2018 Aug 3:1-10. doi: 10.1080/10245332.2018.1505225. [Epub ahead of print]

PMID:
30073913
5.

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.

Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, Hall G, Riddell A, Percy CL, Hay CR, Hart DP.

Haemophilia. 2018 May;24(3):344-347. doi: 10.1111/hae.13495.

PMID:
30070072
6.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J.

Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Review.

7.

Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A.

Batty P, Hart DP, Platton S.

Int J Lab Hematol. 2018 May 18. doi: 10.1111/ijlh.12862. [Epub ahead of print]

PMID:
29777571
8.

Individualized PK-based prophylaxis in severe haemophilia.

Dargaud Y, Delavenne X, Hart DP, Meunier S, Mismetti P.

Haemophilia. 2018 Mar;24 Suppl 2:3-17. doi: 10.1111/hae.13397. Review.

PMID:
29543364
9.

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.

Collins P, Chalmers E, Alamelu J, Hay C, Liesner R, Makris M, Mathias M, Payne J, Rangarajan S, Richards M, Talks K, Tunstall O, Williams M, Hart DP.

Haemophilia. 2017 Sep;23(5):654-659. doi: 10.1111/hae.13264. Epub 2017 Jun 2. No abstract available.

PMID:
28574205
10.

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.

Batty P, Austin SK, Khair K, Millar CM, Palmer B, Rangarajan S, Stümpel JP, Thanigaikumar M, Yee TT, Hart DP.

Br J Haematol. 2017 Mar;176(5):796-804. doi: 10.1111/bjh.14543. Epub 2017 Feb 15.

11.

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients.

van Os SB, Troop NA, Sullivan KR, Hart DP.

PLoS One. 2017 Jan 19;12(1):e0169880. doi: 10.1371/journal.pone.0169880. eCollection 2017.

12.

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.

Sivapalaratnam S, Westbury SK, Stephens JC, Greene D, Downes K, Kelly AM, Lentaigne C, Astle WJ, Huizinga EG, Nurden P, Papadia S, Peerlinck K, Penkett CJ, Perry DJ, Roughley C, Simeoni I, Stirrups K, Hart DP, Tait RC, Mumford AD; NIHR BioResource, Laffan MA, Freson K, Ouwehand WH, Kunishima S, Turro E.

Blood. 2017 Jan 26;129(4):520-524. doi: 10.1182/blood-2016-08-732248. Epub 2016 Nov 14.

13.

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E.

Blood. 2016 Jun 9;127(23):2791-803. doi: 10.1182/blood-2015-12-688267. Epub 2016 Apr 15.

14.

A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.

Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D, Young G, Luddington RJ.

J Thromb Haemost. 2016 Apr;14(4):757-64. doi: 10.1111/jth.13253. Epub 2016 Feb 18.

15.

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.

van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Hart DP, Hamulyak K, Klamroth R, Meijer K, Nijziel M, Schinco P, Yee TT, van der Bom JG, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2016 Mar;115(3):543-50. doi: 10.1160/TH15-03-0212. Epub 2015 Nov 19.

PMID:
26582077
16.

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.

Batty P, Moore GW, Platton S, Maloney JC, Palmer B, Bowles L, Pasi KJ, Rangarajan S, Hart DP.

Thromb Haemost. 2015 Oct;114(4):804-11. doi: 10.1160/TH14-12-1062. Epub 2015 Jun 11.

PMID:
26063073
17.

Computational prediction of phenotype in haemophilia A.

Batty P, Hart DP.

Haemophilia. 2015 Sep;21(5):659-61. doi: 10.1111/hae.12694. Epub 2015 May 8. No abstract available.

PMID:
25952765
18.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16.

PMID:
25879247
19.

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres.

Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK.

Haemophilia. 2015 Jul;21(4):490-5. doi: 10.1111/hae.12682. Epub 2015 Apr 9.

PMID:
25855341
20.

A national survey of immunosuppression strategies for acquired haemophilia A.

Batty P, Palmer B, Chalmers E, Hay CR, Liesner R, Rangarajan S, Talks K, Williams M, Collins P, Hart DP.

Haemophilia. 2015 Jan;21(1):e73-6. doi: 10.1111/hae.12547. Epub 2014 Nov 24. No abstract available.

PMID:
25422109
21.

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.

Hay CR, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Collins PW.

Haemophilia. 2015 Mar;21(2):219-26. doi: 10.1111/hae.12563. Epub 2014 Nov 7.

PMID:
25382829
22.

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Collins PW, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR; UK Haemophilia Centre Doctors’ Organization.

Blood. 2014 Nov 27;124(23):3389-97. doi: 10.1182/blood-2014-07-580498. Epub 2014 Oct 22.

23.

A large-scale computational study of inhibitor risk in non-severe haemophilia A.

Shepherd AJ, Skelton S, Sansom CE, Gomez K, Moss DS, Hart DP.

Br J Haematol. 2015 Feb;168(3):413-20. doi: 10.1111/bjh.13131. Epub 2014 Sep 22.

PMID:
25244644
24.

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.

Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ.

Haemophilia. 2014 Nov;20(6):846-53. doi: 10.1111/hae.12496. Epub 2014 Aug 7.

PMID:
25102895
25.

Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A.

Batty P, Platton S, Bowles L, Pasi KJ, Hart DP.

Br J Haematol. 2014 Sep;166(6):953-6. doi: 10.1111/bjh.12923. Epub 2014 May 9. No abstract available.

PMID:
24809434
26.

Computational modelling and inhibitor risk: predicting the future?

Hart DP.

Haemophilia. 2014 Mar;20(2):155-7. doi: 10.1111/hae.12332. Epub 2014 Jan 7. No abstract available.

PMID:
24393500
27.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

28.

The incidence and magnitude of fibrinolytic activation in trauma patients.

Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K.

J Thromb Haemost. 2013 Feb;11(2):307-14. doi: 10.1111/jth.12078.

29.

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.

Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR; UK Haemophilia Centre Doctors.

Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15. No abstract available.

PMID:
23157203
30.

Rapid skin permeabilization by the simultaneous application of dual-frequency, high-intensity ultrasound.

Schoellhammer CM, Polat BE, Mendenhall J, Maa R, Jones B, Hart DP, Langer R, Blankschtein D.

J Control Release. 2012 Oct 28;163(2):154-60. doi: 10.1016/j.jconrel.2012.08.019. Epub 2012 Aug 23.

31.

Should clinicians edit Wikipedia to engage a wider world web?

Kint M, Hart DP.

BMJ. 2012 Jul 3;345:e4275. doi: 10.1136/bmj.e4275. No abstract available.

PMID:
22761090
32.

Access to primary dental care for patients with inherited bleeding disorders.

Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP.

Haemophilia. 2012 Jul;18(4):510-5. doi: 10.1111/j.1365-2516.2011.02716.x. Epub 2011 Dec 12.

PMID:
22151066
33.

C. elegans Notch signaling regulates adult chemosensory response and larval molting quiescence.

Singh K, Chao MY, Somers GA, Komatsu H, Corkins ME, Larkins-Ford J, Tucey T, Dionne HM, Walsh MB, Beaumont EK, Hart DP, Lockery SR, Hart AC.

Curr Biol. 2011 May 24;21(10):825-34. doi: 10.1016/j.cub.2011.04.010. Epub 2011 May 5.

34.

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.

Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ.

Haematologica. 2010 Jan;95(1):126-34. doi: 10.3324/haematol.2009.006486. Epub 2009 Aug 13.

35.

Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.

Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ.

Gene Ther. 2008 Apr;15(8):625-31. doi: 10.1038/sj.gt.3303078. Epub 2008 Feb 28.

PMID:
18305579
36.

Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.

Thomas S, Xue SA, Cesco-Gaspere M, San José E, Hart DP, Wong V, Debets R, Alarcon B, Morris E, Stauss HJ.

J Immunol. 2007 Nov 1;179(9):5803-10.

37.

WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.

Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6. Epub 2007 Sep 12. Review.

PMID:
17855129
38.

T-cell receptor gene therapy for cancer: the progress to date and future objectives.

Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1207-18. Review.

PMID:
17696819
39.

Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies.

Hart DP, Peggs KS.

Clin Pharmacol Ther. 2007 Sep;82(3):325-9. Epub 2007 Jul 18. Review.

PMID:
17637786
40.

Monoclonal T-cell receptors: new reagents for cancer therapy.

Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A, Wright G, Perro M, Little AM, Pospori C, King J, Morris EC.

Mol Ther. 2007 Oct;15(10):1744-50. Epub 2007 Jul 17. Review.

41.

The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.

Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S.

Bone Marrow Transplant. 2005 Jun;35(11):1065-9.

PMID:
15806119
42.

Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.

Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Mackinnon S.

Br J Haematol. 2005 Mar;128(6):824-9.

PMID:
15755287
43.

Vascular and brain neuropeptide Y in banded and spontaneously hypertensive rats.

Morris MJ, Tortelli CF, Hart DP, Delbridge LM.

Peptides. 2004 Aug;25(8):1313-9.

PMID:
15350699
44.

Excitation nonlinearities in emission reabsorption laser-induced fluorescence techniques.

Hidrovo CH, Brau RR, Hart DP.

Appl Opt. 2004 Feb 1;43(4):894-913.

PMID:
14960085
45.

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, Goldstone AH, Linch DC, Mackinnon S.

Blood. 2004 Feb 15;103(4):1548-56. Epub 2003 Oct 23.

46.

Mist deposition onto hairy root cultures: aerosol modeling and experiments.

Wyslouzil BE, Whipple M, Chatterjee C, Walcerz DB, Weathers PJ, Hart DP.

Biotechnol Prog. 1997 Mar-Apr;13(2):185-94.

PMID:
9104040
47.

The role of a community psychiatric nurse in prison healthcare.

Hart DP, Vanderwall CF.

J Clin Forensic Med. 1995 Jun;2(2):81-3.

PMID:
15335653
48.
49.

Acute dorsal fracture-dislocation of the proximal interphalangeal joint.

Hart DP, Blair WF.

J Iowa Med Soc. 1983 Sep;73(9):359-63. No abstract available.

PMID:
6631083
50.

Serum uric acid in England and Scotland.

Sturge RA, Scott JT, Kennedy AC, Hart DP, Buchanan WW.

Ann Rheum Dis. 1977 Oct;36(5):420-7.

Supplemental Content

Support Center